SEC Connect
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of report (date of earliest event
reported): November 10, 2016
INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or Other Jurisdiction of
Incorporation)
|
(Commission File
Number)
|
(IRS Employer Identification
No.)
|
9171
Towne Centre Drive, Suite 440, San Diego, CA 92122
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
(858)
964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial
Condition
Item 7.01 Regulation FD Disclosure
On
November 10, 2016, Innovus Pharmaceuticals, Inc. (the
“Company”) issued a press release setting forth its
results for the quarter ended September 30, 2016. A copy of the
press release is attached hereto as Exhibit 99.1 and is
incorporated by reference herein.
This
information, including the information contained in the press
release, shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and is not incorporated by reference
into any of the Company’s filings, whether made before or
after the date hereof, regardless of any general incorporation
language in any such filing.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press
Release
|
SIGNATURE
Pursuant
to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
INNOVUS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Date: November
10, 2016
|
By: /s/
Robert E. Hoffman
|
|
|
Robert
E. Hoffman
|
|
|
Executive
Vice President and Chief Financial Officer
|